Kevin Friedman

Founder of Kelonia Therapeutics

Kevin Friedman

Backed by

Sources

Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma — 2022-04

Browse all founders · Browse investors